Back to Research

Organization profile

Bottneuro

Bottneuro is a medtech startup from the University of Basel developing a non-invasive neuromodulation therapy for Alzheimer's disease. The company's Miamind® platform utilizes patient-specific MRI data to deliver targeted electrical stimulation to affected brain regions, aiming to restore cognitive function and manage neurodegeneration at home.

Basel, SwitzerlandFounded 2021

Overview

1. Executive Summary (Confidence: High)

Bottneuro is pioneering "the new pharma" for neurological diseases, focusing on personalized, non-invasive therapies for Alzheimer's.[40] Founded in 2021 as a spin-off from the University of Basel, the company has developed the Miamind® neurostimulator, a customized 3D-printed helmet that delivers transcranial alternating current stimulation (tACS).[40] Following the successful completion of its first clinical study (Mindstim), which met all safety outcomes and showed a 38% increase in patient attention, Bottneuro launched a Priority Access Program in Switzerland in 2025.[40] The device is registered under MDR as a Custom-Made Device, allowing neurologists to prescribe it for independent, at-home use.[40] With a market opportunity exceeding $500 billion, Bottneuro aims to make Alzheimer’s a manageable condition while restoring patient independence.[40]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.